CardioDynamics Awarded Four New U.S. Patents; Novel AERIS--TM-- Signal Processing Covered.

Business Editors/Health/Medical Writers

BIOWIRE2K

SAN DIEGO--(BUSINESS WIRE)--June 3, 2003

CardioDynamics (Nasdaq:CDIC), the innovator and leader of Impedance Cardiography (ICG) technology and manufacturer of BioZ(R) noninvasive cardiac function monitoring systems, today announced it has been awarded four U.S. patents.

The first patent covers the company's ICG signal processing and three relate to the unique design features of its BioZtect(R) sensor system. The company's patent portfolio now includes five issued patents, two licensed patents, and six patents pending.

U.S. Patent No. 6,561,986, "Method and Apparatus for Hemodynamic Assessment Including Fiducial Point Detection," contains 46 claims and is a strategic patent underlying the company's novel AERIS(TM) (Adaptive Extraction & Recognition of Impedance Signals) processing. AERIS(TM) utilizes breakthrough techniques in time-scale signal processing to filter and accurately determine key impedance (ICG) and electrocardiographic (ECG) waveform characteristics, known as "fiducial points." ICG and ECG fiducial points form the core measurements from which BioZ parameters are determined. AERIS(TM) processing provides enhanced stability, accuracy and reproducibility in a broader range of patient monitoring conditions.

U.S. Patent Nos. D468,433, D471,281 and D475,138 cover the design aspects of the company's BioZtect sensors. The intellectual property protection applies to sensors for use with both its BioZ ICG Monitor and with GE Medical Systems' BioZ ICG Module. The BioZtect sensors offer notable improvements in safety and signal transmission and detection, which are critical for device performance.

Michael K. Perry, CEO of CardioDynamics, stated, "As the innovator and leader of ICG, we continue to strengthen our intellectual property portfolio to diminish the threat of potential competitive products. AERIS(TM) is the future of ICG signal processing and is strategic for the continued superiority of our methods for measuring cardiac function. Additionally, adding patent protection to our proprietary sensors is an important factor in enhancing our products' performance and growing our sensor revenue stream, which accounted for over 15% of company revenue in the most recent quarter. We are exceptionally proud of our R&D team's ability to consistently advance our core technology and product platforms."

About CardioDynamics:

CardioDynamics (Nasdaq:CDIC), the ICG Company, is the innovator and global leader of breakthrough medical technology called Impedance Cardiography (ICG). The company's BioZ(R) Systems are being used by leading physicians around the world to help battle the number one killer of men and women -- cardiovascular disease. Partners include GE Medical Systems Information Technologies, Philips Medical Systems and Vasomedical. The worldwide market potential for BioZ products is estimated to be $5 billion and an additional $800 million in recurring annual revenue for disposables. For additional information or to request an investor package, refer to the company's Web site at www.cdic.com.

Forward-Looking (Safe Harbor) Statement:

Note: Except for the historical and factual information contained herein, this press release contains forward-looking statements, regarding securing our disposable revenue stream, mitigating competitive threats, estimated cardiovascular and ICG industry prospects, market size, potential, growth and penetration rates, the accuracy of which is necessarily subject to uncertainties and risks including the company's sole dependence on the BioZ product line, and various uncertainties characteristic of early growth companies, as well as other risks detailed in the company's filings with the SEC, including its 2002 Form 10-K. The company does not undertake to update the disclosures contained in this press release.